Pfizer announced on Thursday that it has begun studying a third dose of its COVID-19 vaccine, part of a strategy to guard against mutated versions of the coronavirus.
Health authorities say first-generation COVID-19 vaccines still protect against variants that are emerging in different parts of the world. But manufacturers are starting to prepare now in case a more vaccine-resistant mutation comes along.
Pfizer said it will offer a third dose to 144 volunteers, drawing from people who participated in the vaccine’s early-stage U.S. testing last year. It wants to determine if an additional booster shot given six to 12 months after the first two doses would rev up the immune system enough to ward off a mutated virus.
Pfizer and its German partner, BioNTech, also are tweaking their vaccine recipe. The companies are in discussions with U.S. and European regulators about a study to evaluate doses updated to better match variants such as the one first discovered in South Africa.
A letter from the Editor
Dear reader,
We have been keeping you up-to-date with information on the developments in India and the world that have a bearing on our health and wellbeing, our lives and livelihoods, during these difficult times. To enable wide dissemination of news that is in public interest, we have increased the number of articles that can be read free, and extended free trial periods. However, we have a request for those who can afford to subscribe: please do. As we fight disinformation and misinformation, and keep apace with the happenings, we need to commit greater resources to news gathering operations. We promise to deliver quality journalism that stays away from vested interest and political propaganda.
Support Quality Journalism
A letter from the Editor
Dear subscriber,
Thank you!
Your support for our journalism is invaluable. It’s a support for truth and fairness in journalism. It has helped us keep apace with events and happenings.
The Hindu has always stood for journalism that is in the public interest. At this difficult time, it becomes even more important that we have access to information that has a bearing on our health and well-being, our lives, and livelihoods. As a subscriber, you are not only a beneficiary of our work but also its enabler.
We also reiterate here the promise that our team of reporters, copy editors, fact-checkers, designers, and photographers will deliver quality journalism that stays away from vested interest and political propaganda.
Suresh Nambath
